Table 2 Univariate and Multivariate analyses of prognostic factors in patients with PMOC presenting for curative-intent CRS

Age (cont)

1.01 (0.99–1.02)

0.35

1.01 (0.99–1.03)

0.19

BMI (cont)

1.00 (0.97–1.03)

0.91

1.01 (0.97–1.05)

0.76

CA125 pre-Tx > 321 u/ml

1.27 (0.91–1.77)

0.16

1.25 (0.85–1.85)

0.25

CA 125 post-Tx > 38 u/ml

1.11 (0.80–1.55)

0.51

1.39 (0.94–2.07)

0.09

1.13 (0.74–1.74)

0.57

NAC

0.88 (0.62–1.25)

0.47

0.93 (0.62–1.39)

0.73

FIGO

III vs II

2.62 (1.15-

0.02

1.81 (0.78-

0.17

3.73 (1.17-

0.025

2.52 (0.76-

0.13

IVa vs II

5.97)

3.01 (1.21–7.44)

0.17

4.24)

1.88 (0.73–4.82)

0.19

11.8)

5.35 (1.56–18.3)

0.008

8.31)

3.43 (0.96–12.27)

0.05

PCI > 8

1.97 (1.41–2.76)

 < 0.001

1.78 (1.25–2.53)

0.001

2.16 (1.45–3.24)

 < 0.001

1.87 (1.20–2.91)

0.005

Primary tumor histology:

Serous vs Other or mixed

0.76 (0.44–1.31)

0.32

0.92 (0.50–1.69)

0.79

Degree of differentiation:

Moderate vs well

2.04 (0.96–4.32)

0.06

2.04 (0.96–4.32)

0.06

2.51 (1.11–5.68)

0.027

2.19 (0.95–5.04)

0.06

Poor vs well

2.20 (1.15–4.22)

0.01

2.03 (1.06–3.89)

0.03

1.84 (0.89–3.83)

0.099

1.53 (0.73–2.21)

0.26

Positive LN status

0.96 (0.67–1.38)

0.86

0.99 (0.65–1.50)

0.97

HIPEC

0.83 (0.47–1.46)

0.52

0.86 (0.44–1.65)

0.65

CD complication:

CD 0-I-II vs CD III-IV

1.14 (0.71–1.83)

0.59

1.19 (0.69–2.03)

0.52

Positive PST

1.35 (0.92–1.99)

0.12

1.15 (0.77–1.70)

0.49

1.01 (0.62–1.61)

0.97